CORXEL
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

CORXEL Trademark

Serial Number: 79417612

CORXEL is a trademark filed by Ji Xing Pharmaceuticals (Shanghai) Co., Ltd. on September 29, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

Ji Xing Pharmaceuticals (Shanghai) Co., Ltd. (10 trademarks)

Room 2801, Level 28,

Entity Type: 99

Trademark Details

Filing Date

September 29, 2024

Registration Date

Not Registered

Published for Opposition

August 19, 2025

Goods & Services

Monitoring pharmaceutical, veterinary and sanitary preparations, medical supplies and drug for quality control purposes; quality control for others; quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the field of medicines for the treatment of inflammation, cardiovascular diseases, heart failure, cardiac arrhythmia, coronary heart disease, angina pectoris, myocarditis, hypertension, central nervous system diseases, cerebral hemorrhage, cerebral infarction, metabolic diseases and disorders in the nature of diabetes, kidney diseases, tumors, parasitosis, acariasis, bacterial infection, fungal infection, microbiosis, ophthalmic disorders, rhinopathy, edema, cirrhosis ascites; scientific research and development; chemical research services; pharmaceutical research services; scientific research in the nature of conducting clinical trials for others in the field of inflammation, cardiovascular diseases, heart failure, cardiac arrhythmia, coronary heart disease, angina pectoris, myocarditis, hypertension, central nervous system diseases, cerebral hemorrhage, cerebral infarction, metabolic diseases and disorders in the nature of diabetes, kidney diseases, tumors, parasitosis, acariasis, bacterial infection, fungal infection, microbiosis, ophthalmic disorders, rhinopathy, edema, cirrhosis ascites; medical and scientific research, namely, conducting clinical trials for others; medical and scientific research in the field of inflammation, cardiovascular diseases, heart failure, cardiac arrhythmia, coronary heart disease, angina pectoris, myocarditis, hypertension, central nervous system diseases, cerebral hemorrhage, cerebral infarction, metabolic diseases and disorders in the nature of diabetes, kidney diseases, tumors, parasitosis, acariasis, bacterial infection, fungal infection, microbiosis, ophthalmic disorders, rhinopathy, edema, cirrhosis ascites; development of pharmaceutical preparations and medicines; pharmaceutical drug development services; pharmaceutical product evaluation for laboratory purposes; testing of pharmaceuticals for laboratory purposes; packaging design

Anti-inflammatories; cardiovascular pharmaceutical preparations; medicines for human purposes, namely, medicines for the treatment of degenerative disease, motor neuron disease; medicines for human purposes, namely, medicines for the treatment of epilepsy; medicines for human purposes, namely, medicines for the treatment of macular degeneration; medicines for human purposes, namely, medicines for the treatment of cardiovascular disease, coronary heart disease, angina pectoris, myocarditis, cardiac arrhythmia, tumors, infectious diseases, autoimmune disease, blood disease, mental illness, ophthalmic disorders, metabolic diseases and disorders in the nature of diabetes, kidney diseases, osteoporosis; antiviral medicines; medicines for human purposes, namely, biological products, prepared by using biological materials in the nature of microorganisms, cells, and various animal and human tissues and liquids, obtained by biological techniques, namely, genetic engineering, cell engineering, protein engineering, fermentation engineering for the treatment of central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases, antipyretic and analgesic purposes, non-steroidal anti-inflammatory purposes, infectious diseases, autoimmune diseases, anti-tumor purposes, hypoglycemic and diuretic purposes, vitamin and hormonal purposes; medicines for human purposes, namely, parenteral nutritional supplements; pharmaceutical preparations acting on the central nervous system; cerebral hemorrhage prophylactic agents; pharmaceutical preparations for the treatment of heart rhythm disorders; antiarrhythmics; cardiovascular agents for medical purposes; nutritive substances for microorganisms for medical purposes; nutritive substances for microorganism cultures for medical or veterinary purposes; pharmaceutical preparations for treating hypertension; nasal spray preparations; ophthalmic preparations; eye drops; chemical preparations for pharmaceutical or medical purposes, namely, for the treatment of inflammation, cardiovascular diseases, heart failure, cardiac arrhythmia, coronary heart disease, angina pectoris, myocarditis, hypertension, central nervous system diseases, cerebral hemorrhage, cerebral infarction, metabolic diseases and disorders in the nature of diabetes, kidney diseases, tumors, parasitosis, acariasis, bacterial infection, fungal infection, microbiosis, ophthalmic disorders, rhinopathy, edema, cirrhosis ascites; drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; raw material drugs, namely, pharmaceuticals for the treatment of inflammation, cardiovascular diseases, heart failure, cardiac arrhythmia, coronary heart disease, angina pectoris, myocarditis, hypertension, central nervous system diseases, cerebral hemorrhage, cerebral infarction, metabolic diseases and disorders in the nature of diabetes, kidney diseases, tumors, parasitosis, acariasis, bacterial infection, fungal infection, microbiosis, ophthalmic disorders, rhinopathy, edema, cirrhosis ascites; antihypertensives; diuretic preparations; medicines for the treatment of cardiovascular and cerebrovascular diseases; dietetic preparations adapted for medical purposes; dietetic foods and beverages adapted for medical use; dietetic infusions for medical use

Wholesale store services for pharmaceutical and veterinary preparations and medical supplies; retail store services for pharmaceutical and veterinary preparations and medical supplies; wholesale and retail store services featuring medical supplies; wholesale and retail store services featuring medicines; wholesale and retail store services featuring pharmaceutical preparations

Filing History

REFUSAL PROCESSED BY IB
Mar 5, 2026 RFNT
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Feb 15, 2026 ETOP
OPPOSITION INSTITUTED NO. 999999
Feb 12, 2026 OP.I
OPPOSITION NOTICE (IB REFUSAL) SENT TO IB
Feb 10, 2026 OPNS
OPPOSITION NOTICE (IB REFUSAL) CREATED
Feb 10, 2026 OPNC
EXTENSION OF TIME TO OPPOSE RECEIVED
Sep 19, 2025 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 19, 2025 NPUB
PUBLISHED FOR OPPOSITION
Aug 19, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 13, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 14, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 9, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 9, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 9, 2025 TROA
REFUSAL PROCESSED BY IB
May 24, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
May 6, 2025 RFCS
REFUSAL PROCESSED BY MPU
May 6, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 20, 2025 RFCR
NON-FINAL ACTION WRITTEN
Mar 19, 2025 CNRT
ASSIGNED TO EXAMINER
Mar 19, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Mar 14, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 14, 2025 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Mar 14, 2025 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 20, 2025 REPR